{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Incidence of toxicity related to VAC treatment in patients with CYP2B6 genotypes.","groups":[{"description":"Patients receive VAC chemotherapy comprising vincristine IV over 1 minute on day 1 of weeks 1-13, 16, 19-25, 28, 31-37, and 40; dactinomycin IV over 1-5 minutes on day 1 of weeks 1, 4, 13, 16, 19, 22, 25, 28, 31, 34, 37,and 40; and cyclophosphamide IV over 1 hour on day 1 of weeks 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, and 40. Patients may also undergo radiotherapy 5 days a week for 4-6 weeks beginning in week 4.","id":"OG000","title":"Vincristine, Dactinomycin, Cyclophosphamide (VAC)"}],"populationDescription":"The analysis was abandoned due to low incidence of toxicity. Data were not collected.","reportingStatus":"POSTED","timeFrame":"During the study","title":"Toxicity With CYP2B6 Genotypes","type":"SECONDARY"}